Skip to main content
Enveric Biosciences, Inc. logo

Enveric Biosciences, Inc. — Investor Relations & Filings

Ticker · ENVB ISIN · US02362F3029 US Professional, scientific and technical activities
Open in API
Filings indexed 1,028 across all filing types
Latest filing 2024-05-17 Delisting Announcement
Country US United States of America
Listing US ENVB

About Enveric Biosciences, Inc.

https://www.enveric.com/

Enveric Biosciences is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of neuropsychiatric disorders. The company focuses on conditions such as anxiety, depression, and addiction. Leveraging its proprietary discovery and development platform, The Psybrary™, Enveric has created a robust intellectual property portfolio of novel molecules for specific mental health indications. Its development pipeline includes candidates such as EB-003 for difficult-to-treat mental health disorders and the EVM301 series.

Recent filings

Filing Released Lang Actions
Delisting Announcement 2024
Delisting Announcement Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by Enveric Biosciences, Inc. dated May 16, 2024. The key content is a notification from Nasdaq regarding the company's failure to meet the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The document details the delisting notice, the compliance period, and potential next steps including a reverse stock split or appeal. This is a regulatory announcement about the company's listing status rather than a financial report or earnings release. The presence of Nasdaq delisting rules and the nature of the content clearly identify this as a Delisting Announcement.
2024-05-17 English
Interim / Quarterly Report 2024
Interim / Quarterly Report Q1 2024
2024-05-15 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 15, 2024, by Enveric Biosciences, Inc. It reports a press release announcing financial results for the first quarter ended March 31, 2024. The text explicitly states that the press release is furnished as an exhibit and incorporated by reference, and the document itself is a current report rather than the full financial report. The document length is 4271 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document that announces or furnishes a report but does not contain the full financial data should be classified as a Regulatory Filing (RNS), as it does not contain the full quarterly report or detailed financial statements itself but rather a press release summary. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-05-15 English
Capital/Financing Update 2024
Capital/Financing Update Classification · 100% confidence The document is a Form 424B5 prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act. It details a registered direct offering of common stock, including the number of shares offered, pricing, and terms of the offering. The text includes references to the registration statement, offering details, risk factors, use of proceeds, and legal matters. This type of filing is a capital raising document providing updates on financing activities and terms of securities issuance. It is not an annual or quarterly report, audit report, earnings release, or other types of filings. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the actual offering document, not just an announcement or certification.
2024-05-03 English
Capital/Financing Update 2024
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 3, 2024, by Enveric Biosciences, Inc. It reports the entry into a material definitive agreement involving a registered direct offering of common stock shares. The content focuses on the details of the stock purchase agreements, the terms of the offering, and related legal opinions. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is a current report disclosing a significant corporate event related to capital raising and stock issuance agreements. This fits the definition of a Capital/Financing Update (CAP). The document length is over 6,000 characters and contains substantive details about the financing transaction, not merely an announcement or a brief notice. Therefore, the appropriate classification is CAP with high confidence.
2024-05-03 English
Annual Report 2024
Annual Report
2024-04-16 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.